{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:57:08Z","timestamp":1795021028105,"version":"4.10.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Plan Nacional R+D+I"},{"name":"Red de Investigaci\u00f3n en SIDA","award":["RD16\/0025\/0020-ISCIII-FEDER"],"award-info":[{"award-number":["RD16\/0025\/0020-ISCIII-FEDER"]}]},{"name":"Miguel Servet research grant","award":["CPII18\/00033"],"award-info":[{"award-number":["CPII18\/00033"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.03.029","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T08:51:39Z","timestamp":1554886299000},"page":"2758-2763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-1013","authenticated-orcid":false,"given":"Karin","family":"Neukam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Llaves-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.03.029_b0005","unstructured":"World Health Organization. Hepatitis B Fact Sheet (updated April 2017). Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/. Accessed: November 20th 2017."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.03.029_b0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/liv.13304","article-title":"Future anti-HBV strategies","volume":"37","author":"Gane","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.vaccine.2019.03.029_b0015","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection","volume":"49","author":"McMahon","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2019.03.029_b0020","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/0264-410X(90)90222-8","article-title":"Overview of a 5-yr clinical experience with a yeast derived hepatitis B vaccine","volume":"8","author":"Andr\u00e9","year":"1990","journal-title":"Vaccine"},{"issue":"suppl 1","key":"10.1016\/j.vaccine.2019.03.029_b0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0264-410X(95)93547-M","article-title":"Global programmeme for control of hepatitis B infection","volume":"13","author":"Kane","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.029_b0030","unstructured":"GlaxoSmithKline Biologicals. Engerix-B prescribing information. Available at: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm224503.pdf. Accessed: April 20th, 2018."},{"key":"10.1016\/j.vaccine.2019.03.029_b0035","unstructured":"Merck Sharp & Dohme Corp. Recombivax\u00ae prescribing information. Available at: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm110114.pdf. Accessed: April 20th, 2018."},{"key":"10.1016\/j.vaccine.2019.03.029_b0040","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0264-410X(00)00217-6","article-title":"A comparison of two commercial recombinant vaccines for hepatitis B in adolescents","volume":"19","author":"Leroux-Roels","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.029_b0045","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14760584.2017.1338568","article-title":"The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience","volume":"16","author":"Van Den Ende","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.03.029_b0050","unstructured":"Centers for Disease Control and Prevention. Hepatitis B Vaccine Information Statement. Available at: https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/hep-b.pdf Accessed: April 20th, 2018."},{"key":"10.1016\/j.vaccine.2019.03.029_b0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/jac\/dkp479","article-title":"Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe","volume":"65","author":"Soriano","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.vaccine.2019.03.029_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142515","article-title":"High prevalence and high incidence of coinfection with hepatitis B, hepatitis C, and syphilis and low rate of effective vaccination against hepatitis B in HIV-positive men who have sex with men with known date of hiv seroconversion in Germany","volume":"10","author":"Jansen","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.vaccine.2019.03.029_b0065","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/infdis\/163.3.454","article-title":"Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection","volume":"163","author":"Hadler","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.029_b0070","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.03.029_b0075","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1086\/599110","article-title":"Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis","volume":"48","author":"Nikolopoulos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.029_b0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2007.11.009","article-title":"Viral hepatitis and HIV coinfection","volume":"48","author":"Sulkowski","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2019.03.029_b0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2019.03.029_b0090","unstructured":"British HIV Association 2015. British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015. Available at: http:\/\/www.bhiva.org\/documents\/Guidelines\/Vaccination\/2015-Vaccination-Guidelines.pdf. Accessed April 20th, 2018."},{"key":"10.1016\/j.vaccine.2019.03.029_b0095","first-page":"111","article-title":"Management of the hepatitis B virus\/HIV-infected patient","volume":"23","author":"Sherman","year":"2015","journal-title":"HBV\/HIV Coinfection"},{"key":"10.1016\/j.vaccine.2019.03.029_b0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1086\/433180","article-title":"Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons","volume":"41","author":"Overton","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.029_b0105","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1080\/21645515.2015.1055424","article-title":"Hepatitis B and A vaccination in HIV-infected adults: A review","volume":"11","author":"Mena","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.03.029_b0110","unstructured":"Spanish Agency for Medicines and Sanitary Products. Fact Sheet Engerix-B. Available at: https:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/60653\/FT_60653.pdf. Accessed: April 20th, 2018."},{"key":"10.1016\/j.vaccine.2019.03.029_b0115","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of Protection Induced by Vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immuno"},{"key":"10.1016\/j.vaccine.2019.03.029_b0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2019.03.029_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1277844","article-title":"Hepatitis B virus vaccination in HIV-infected people: a review","volume":"13","author":"Catherine","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.03.029_b0130","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1310\/hct1105-332","article-title":"Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients","volume":"11","author":"Pettit","year":"2010","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.vaccine.2019.03.029_b0135","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.ijid.2008.05.1226","article-title":"Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults","volume":"12","author":"Bailey","year":"2008","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.029_b0140","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.vaccine.2004.11.057","article-title":"Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose","volume":"23","author":"Fonseca","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.029_b0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jiph.2012.11.001","article-title":"Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort","volume":"6","author":"Rock","year":"2013","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.vaccine.2019.03.029_b0150","first-page":"680","article-title":"Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients","volume":"38","author":"Ungulkraiwit","year":"2007","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.vaccine.2019.03.029_b0155","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1258\/ijsa.2007.007197","article-title":"Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons","volume":"19","author":"Kim","year":"2008","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.vaccine.2019.03.029_b0160","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.vaccine.2016.02.055","article-title":"CD4\/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: a prospective cohort study","volume":"34","author":"Fuster","year":"2016","journal-title":"Vaccine"},{"issue":"S1","key":"10.1016\/j.vaccine.2019.03.029_b0165","first-page":"1","article-title":"Importance of serologic control after vacunation against hepatitis B virus infection in HIV-infected patients","volume":"22","author":"Valera","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"RR-16","key":"10.1016\/j.vaccine.2019.03.029_b0170","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on ImmunizationPractices (ACIP) Part II: immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2019.03.029_b0175","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1016\/j.vaccine.2012.03.018","article-title":"Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice","volume":"30","author":"Mena","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.029_b0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0956462412472309","article-title":"Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis?","volume":"24","author":"Ni","year":"2013","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.vaccine.2019.03.029_b0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vaccine.2008.10.040","article-title":"Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients","volume":"27","author":"Cruciani","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.029_b0190","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1016\/j.vaccine.2012.07.028","article-title":"Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults","volume":"30","author":"Potsch","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.029_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080409","article-title":"Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial","volume":"8","author":"Chaiklang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.03.029_b0200","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.1302596","article-title":"Multiparametric bioinformatics distinguish the CD4\/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection","volume":"192","author":"Buggert","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.029_b0205","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.03.029_b0210","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/infdis\/jis695","article-title":"Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in","volume":"207","author":"IrunguE","year":"2013","journal-title":"Kenya. J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.029_b0215","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1086\/524690","article-title":"prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients","volume":"197","author":"A de Vries-Sluijs","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.029_b0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-6405-3-9","article-title":"Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses","volume":"3","author":"Cornejo-Ju\u00e1rez","year":"2006","journal-title":"AIDS Res Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:20Z","timestamp":1759401140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19303512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":44,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19303512"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}